391,274 Shares in Chimerix, Inc. (NASDAQ:CMRX) Acquired by Walleye Capital LLC

Walleye Capital LLC bought a new stake in shares of Chimerix, Inc. (NASDAQ:CMRX) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 391,274 shares of the biopharmaceutical company’s stock, valued at approximately $1,362,000. Walleye Capital LLC owned approximately 0.44% of Chimerix as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in CMRX. Assenagon Asset Management S.A. raised its holdings in shares of Chimerix by 154.8% in the fourth quarter. Assenagon Asset Management S.A. now owns 817,739 shares of the biopharmaceutical company’s stock valued at $2,846,000 after acquiring an additional 496,823 shares in the last quarter. Charles Schwab Investment Management Inc. bought a new stake in shares of Chimerix in the 4th quarter valued at about $183,000. Rosalind Advisors Inc. purchased a new stake in shares of Chimerix in the 4th quarter worth approximately $10,614,000. Palumbo Wealth Management LLC purchased a new stake in shares of Chimerix in the 4th quarter worth approximately $221,000. Finally, Valeo Financial Advisors LLC increased its holdings in Chimerix by 78.8% during the fourth quarter. Valeo Financial Advisors LLC now owns 146,186 shares of the biopharmaceutical company’s stock valued at $509,000 after buying an additional 64,420 shares during the period. 45.42% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CEO Michael T. Andriole sold 7,370 shares of the firm’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $4.52, for a total value of $33,312.40. Following the completion of the transaction, the chief executive officer now owns 609,603 shares in the company, valued at $2,755,405.56. This trade represents a 1.19 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Over the last quarter, insiders sold 20,760 shares of company stock valued at $91,175. Insiders own 13.10% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on the company. StockNews.com started coverage on Chimerix in a report on Wednesday. They set a “hold” rating for the company. HC Wainwright reaffirmed a “neutral” rating and set a $8.55 price objective (down previously from $11.00) on shares of Chimerix in a research report on Wednesday, March 5th. Wedbush reiterated a “neutral” rating and issued a $8.55 target price (up previously from $7.00) on shares of Chimerix in a research note on Wednesday, March 5th. Finally, Jefferies Financial Group reissued a “hold” rating and set a $8.50 price target (down from $10.00) on shares of Chimerix in a research report on Wednesday, March 5th.

Chimerix Price Performance

Shares of CMRX stock opened at $8.54 on Friday. The stock’s fifty day moving average price is $7.39 and its 200 day moving average price is $3.99. Chimerix, Inc. has a 1-year low of $0.75 and a 1-year high of $8.55. The company has a market cap of $801.09 million, a price-to-earnings ratio of -9.09 and a beta of -0.17.

Chimerix (NASDAQ:CMRX) last issued its quarterly earnings results on Friday, March 21st. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.01. The business had revenue of $0.06 million for the quarter, compared to analysts’ expectations of $0.31 million. As a group, equities research analysts anticipate that Chimerix, Inc. will post -0.99 earnings per share for the current year.

Chimerix Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.